ArticleFrontiers in oncology2025
Laryngeal sarcomatoid carcinoma: a case report and literature review on potential molecular targets for therapeutic opportunities.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical features and prognostic factors for spinal metastasis from sarcomatoid carcinoma: identifying candidates suitable for surgical intervention.BMC musculoskeletal disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Laryngeal sarcomatoid carcinoma (LSC) is a rare variant of laryngeal malignancies characterized by an aggressive nature and poor prognosis, predominantly affecting older males. Although early diagnosis may facilitate organ preservation through adjuvant chemotherapy and radiation therapy, advanced stages of the disease, as classified by the TNM system, necessitate a deeper understanding of molecular interactions. This understanding could potentially yield improved molecularly targeted therapeutic opportunities and early diagnosis that likely support the treatment benefits in the LSC. Therefore, this study aims to identify possible molecular targets in LSC to better inform therapeutic options and prognostic markers for obtaining treatment benefits, alongside presenting a case study of a patient with LSC who was admitted to our department.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.